In the field of tumor immunotherapy, tumor antigen escape and the harsh tumor microenvironment (TME) present challenges that would require the development of novel tumor-targeting molecules such as single chain variable fragments (scFv) and nanobodies, or novel engineered protein modulators. Therefore, in collaboration with TMU BIOMED Gloria, GenomeFrontier utilized this platform to successfully develop a number of therapeutic protein candidates for specifically targeting tumor antigens and/or modulating the TME. A brief schematic diagram illustrating how Protein/Target Hunter achieves this is shown in Figure 1:
